Helen Dakin

• Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations.

  Dakin H. and Gray A., (2017), Stat Med, 36, 2814 - 2830

• Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial.

  Violato M. et al, (2016), BMJ Open, 6

• The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block trial.

  Reeves BC. et al, (2016), Health Technol Assess, 20, 1 - 120

• Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L.

  Dixon P. et al, (2016), Qual Life Res, 25, 935 - 945

• Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement.

  Petrou S. et al, (2016), Qual Life Res, 25, 275 - 281

• The Maps Reporting Statement for Studies Mapping onto Generic Preference-Based outcome Measures.

  Petrou S. et al, (2015), Value Health, 18, A715 - A716

• The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.

  Petrou S. et al, (2015), Pharmacoeconomics, 33, 993 - 1011

• Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement.

  Petrou S. et al, (2015), Pharmacoeconomics, 33, 985 - 991

• Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement.

  Petrou S. et al, (2015), Appl Health Econ Health Policy, 13, 437 - 443

• A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).

  Chakravarthy U. et al, (2015), Health Technol Assess, 19, 1 - 298

• Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement.

  Petrou S. et al, (2015), Health Qual Life Outcomes, 13

• Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement.

  Petrou S. et al, (2015), J Med Econ, 18, 851 - 857

• PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT.

  Petrou S. et al, (2015), Int J Technol Assess Health Care, 31, 230 - 235

• Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement

  Petrou S. et al, (2015), Medical Decision Making, 35, NP1 - NP8

• THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE DECISIONS.

  Dakin H. et al, (2014), Health Econ

• Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.

  Dakin HA. et al, (2014), BMJ Open, 4

• A randomised controlled trial of the clinical effectiveness and cost-effectiveness of different knee prostheses: the Knee Arthroplasty Trial (KAT).

  Murray DW. et al, (2014), Health Technol Assess, 18, 1 - viii

• Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database.

  Dakin H., (2013), Health Qual Life Outcomes, 11

• Response mapping to translate health outcomes into the generic health-related quality-of-life instrument EQ-5D: Introducing the mrs2eq and oks2eq commands

  Ramos-Goñni JM. et al, (2013), Stata Journal, 13, 474 - 491

• Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score.

  Dakin H. et al, (2013), Qual Life Res, 22, 683 - 694

• Five-year results of a randomised controlled trial comparing mobile and fixed bearings in total knee replacement.

  Breeman S. et al, (2013), Bone Joint J, 95-B, 486 - 492

• Cost-minimisation analysis versus cost-effectiveness analysis, revisited.

  Dakin H. and Wordsworth S., (2013), Health Econ, 22, 22 - 34

• Cost-minimisation analysis versus cost-effectiveness analysis, revisited

  Dakin H. and Wordsworth S., (2013), Health Economics (United Kingdom), 22, 22 - 34

• Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set.

  Dakin H. et al, (2012), BMJ Open, 2

• Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score

  Dakin H. et al, (2012), Quality of Life Research, 1 - 12

• Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

  Dakin H. et al, (2011), Pharmacoeconomics, 29, 1075 - 1091

• A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia.

  Choy E. et al, (2011), Semin Arthritis Rheum, 41, 335 - 45.e6

• Mixed treatment comparison of repeated measurements of a continuous endpoint: An example using topical treatments for primary open-angle glaucoma and ocular hypertension

  Dakin HA. et al, (2011), Statistics in Medicine, 30, 2511 - 2535

• Patellar resurfacing in total knee replacement: five-year clinical and economic results of a large randomized controlled trial.

  Breeman S. et al, (2011), J Bone Joint Surg Am, 93, 1473 - 1481

• Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.

  Dakin H. et al, (2010), Value Health, 13, 934 - 945

• Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.

  Dakin H. et al, (2010), Value Health, 13, 922 - 933

• NICE'S COST-EFFECTIVENESS THRESHOLD REVISITED: NEW EVIDENCE ON THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE DECISIONS

  Devlin N. et al, (2010), VALUE IN HEALTH, 13, A246 - A246

• Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial.

  Petrou S. et al, (2010), Value Health, 13, 543 - 551

• Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.

  Orme M. et al, (2010), Curr Med Res Opin, 26, 511 - 528

• Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.

  Dakin H. et al, (2010), Qual Life Res, 19, 65 - 80

• A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care.

  Williamson I. et al, (2009), Health Technol Assess, 13, 1 - 144

• A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care.

  Williamson I. et al, (2009), Health technology assessment (Winchester, England), 13, 1 - 144

• Results of a mixed treatment comparison meta-analysis of nucleoside and nucleotide therapies for HBeAG-positive chronic hepatitis B

  Dakin HA. et al, (2008), JOURNAL OF HEPATOLOGY, 48, S256 - S256

• Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.

  Liedgens H. et al, (2008), Clin Drug Investig, 28, 583 - 601

• Cost-effectiveness of erdosteine in the treatment of acute exacerbations of chronic obstructive pulmonary disease

  Haughney J. et al, (2007), THORAX, 62, A47 - A47

• Costutility analysis evaluating the lidocaine 5% medicated plaster relative to gabapentin and pregabalin for postherpetic neuralgia in Germany

  Liedgens H. et al, (2007), VALUE IN HEALTH, 10, A386 - A386

• Cost-utility analysis evaluating lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in Scotland

  Dakin HA. et al, (2007), VALUE IN HEALTH, 10, A9 - A10

• Cost-effectiveness of a lidocaine plaster relative to pregabalin in the treatment of post-herpetic neuralgia in Scotland

  Dakin HA. et al, (2007), VALUE IN HEALTH, 10, A240 - A240

• Cost-effectiveness analysis of the lidocaine 5% medicated plaster relative to gabapentin and pregabalin for post-herpetic neuralgia in Germany

  Liedgens H. et al, (2007), VALUE IN HEALTH, 10, A383 - A384

• Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care.

  Odeyemi IA. et al, (2006), Int J Clin Pract, 60, 949 - 958

• "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.

  Dakin HA. et al, (2006), Health Policy, 77, 352 - 367

• Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre.

  Kalsi V. et al, (2006), Eur Urol, 49, 519 - 527

• "Serious hazards of transfusion" underestimates the incidence of transfusion-related acute lung injury in the UK.

  Riedler GF. and Dakin HA., (2004), Vox Sang, 86

• Cost-effectiveness of clozapine to prevent suicide in schizophrenia: Interim results

  Dakin HA. and Sidhu M., (2003), JOURNAL OF PSYCHOPHARMACOLOGY, 17, A54 - A54

• Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma.

  Riedler GF. et al, (2003), Vox Sang, 85, 88 - 95

• Solvent-detergent-treated plasma may be cost-effective.

  Riedler GF. et al, (2003), Vox Sang, 84

• Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration

  Chakravarthy U. et al, Ophthalmology, 119, 1399 - 1411

• How important is parameter uncertainty around the UK EQ-5D-3L value set when estimating treatment effects?

  Gray A. et al, Joint meeting of the Health Economists' Study Group and the Collège des économistes de la santé Aix-en-Provence, France, 11-13 January 2012

• Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom

  Dakin HA. et al, Clin Ther, 29, 1491 - 1507

Recent Publications

• Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations.

  Dakin H. and Gray A., (2017), Stat Med, 36, 2814 - 2830

• Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial.

  Violato M. et al, (2016), BMJ Open, 6

• The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block trial.

  Reeves BC. et al, (2016), Health Technol Assess, 20, 1 - 120

• Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L.

  Dixon P. et al, (2016), Qual Life Res, 25, 935 - 945

• Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement.

  Petrou S. et al, (2016), Qual Life Res, 25, 275 - 281